Tebipenem Pivoxil
| Catalog No. | KMT050001 |
|---|---|
| CAS No. | 161715-24-8 |
| Formula | C22H31N3O6S2 |
| FW | 497.6 |
| Unit | Price | Stock |
|---|---|---|
| 100 mg | Enquire | Enquire |
| Chemical Name: | (pivaloyloxy)methyl (4R,5S,6S)-3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate |
|---|---|
| Purity: | >95% |
| Storage: | Store at 2-8 deg. C for long term storage |
| Shipping: | Product is stable to be Shipped at Room Temperature |
Tebipenem Pivoxil is chemically (pivaloyloxy)methyl (4R,5S,6S)-3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate .
Tebipenem Pivoxil is supplied with detailed characterization data compliant with regulatory guideline.
Tebipenem Pivoxil can be used for the analytical method development, method validation (AMV), Quality Controlled (QC)
application for Abbreviated New Drug Application (ANDA) or during commercial production of Tebipenem Pivoxil .
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. K.M.Pharma products are for analytical purpose only and not for human use.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. K.M.Pharma products are for analytical purpose only and not for human use.
Related Products
CAT No: KMT050002
CAT No: KMT050003
Tebipenem Pivoxil Impurity 2
CAS No.: 179337-62-3
CAT No.: KMT050003
Formula : C7H12N2O3S2
FW : 236.3
CAT No: KMT050004
CAT No: KMT050005
Tebipenem Pivoxil Impurity 4
CAS No.: 198696-59-2
CAT No.: KMT050005
Formula : C12H18N4S3
FW : 314.5
CAT No: KMT050006
Tebipenem Pivoxil Impurity 5
CAS No.: 90822-22-3
CAT No.: KMT050006
Formula : C23H34N2O7Si
FW : 478.6
CAT No: KMT050007
Tebipenem Pivoxil Impurity 6
CAS No.: 161715-28-2
CAT No.: KMT050007
Formula : C8H12N2OS2
FW : 216.3